Renal function in chronic lithium-treated patients

G Conte1, A Vazzola, E Sacchetti

  • 1Institute of Psychiatry, University of Milan, Italy.

Insights

Lithium carbonate treatment for major affective disorder did not impair renal function in patients. Studies show no negative impact on kidney health, even with long-term use and lower lithium levels.

Area of Science:

  • Nephrology
  • Psychiatry
  • Pharmacology

Background:

  • Lithium carbonate is a common treatment for major affective disorder.
  • Concerns exist regarding potential long-term renal side effects of lithium therapy.

Purpose of the Study:

  • To investigate the effects of chronic lithium carbonate treatment on renal function in patients with major affective disorder.
  • To determine if duration of illness or lithium levels correlate with renal function parameters.

Main Methods:

  • Assessed renal function (urine volume, glomerular filtration rate, urinary osmolality, proteinuria) in 50 patients on chronic lithium carbonate.
  • Administered the DDAVP test to 10 patients to evaluate urinary concentrating ability.
  • Analyzed relationships between renal parameters, illness duration, and serum/red blood cell lithium levels.

Main Results:

  • No significant alterations in urine volume, glomerular filtration rate, urinary osmolality, or proteinuria were observed.
  • No correlation found between renal parameters and duration of illness or lithium levels.
  • DDAVP test showed no impairment in urinary concentrating ability in the tested subgroup.

Conclusions:

  • Chronic lithium carbonate treatment, particularly at lower therapeutic levels, appears safe for renal function in patients with major affective disorder.
  • The study suggests that maintaining lower serum lithium levels may mitigate potential renal risks.
  • Findings contrast with some previous studies, possibly due to differences in patient lithium levels.

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...